Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood - PubMed (original) (raw)

Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood

Heike Runne et al. Proc Natl Acad Sci U S A. 2007.

Abstract

Highly quantitative biomarkers of neurodegenerative disease remain an important need in the urgent quest for disease-modifying therapies. For Huntington's disease (HD), a genetic test is available (trait marker), but necessary state markers are still in development. In this report, we describe a large battery of transcriptomic tests explored as state biomarker candidates. In an attempt to exploit the known neuroinflammatory and transcriptional perturbations of disease, we measured relevant mRNAs in peripheral blood cells. The performance of these potential markers was weak overall, with only one mRNA, immediate early response 3 (IER3), showing a modest but significant increase of 32% in HD samples compared with controls. No statistically significant differences were found for any other mRNAs tested, including a panel of 12 RNA biomarkers identified in a previous report [Borovecki F, Lovrecic L, Zhou J, Jeong H, Then F, Rosas HD, Hersch SM, Hogarth P, Bouzou B, Jensen RV, et al. (2005) Proc Natl Acad Sci USA 102:11023-11028]. The present results may nonetheless inform the future design and testing of HD biomarker strategies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.

Fig. 1.

Relative expression values of candidate biomarker RNAs identified by lymphocyte microarray or whole-blood immune panel gene expression screens. Error bars represent SEM. white, control samples; gray, manifest HD samples (classified as early, moderate, and advanced HD in Table 1). *, nominal P value <0.05.

Fig. 2.

Fig. 2.

Relative expression values of candidate biomarker RNAs identified by HD brain gene expression data. Error bars represent SEM. white, control samples; gray, manifest HD samples (classified as early, moderate, and advanced HD in Table 1).

Fig. 3.

Fig. 3.

Relative expression values of genes identified by ref. . Error bars represent SEM. white, control samples; gray, manifest HD samples (classified as early, moderate, and advanced HD in Table 1).

References

    1. Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, Bhide PG, Vonsattel JP, DiFiglia M. J Neuropathol Exp Neurol. 2001;60:161–172. - PubMed
    1. Hunot S, Hirsch EC. Ann Neurol. 2003;53(Suppl 3):49–58. - PubMed
    1. Singhrao SK, Neal JW, Morgan BP, Gasque P. Exp Neurol. 1999;159:362–376. - PubMed
    1. Bonifati DM, Kishore U. Mol Immunol. 2007;44:999–1010. - PubMed
    1. Leblhuber F, Walli J, Jellinger K, Tilz GP, Widner B, Laccone F, Fuchs D. Clin Chem Lab Med. 1998;36:747–750. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources